ORLANDO — In this video exclusive from the American Diabetes Association Scientific Sessions, Daniel J. Drucker, MD, outlines possible adverse effects of GLP-1 drugs both current and future.
Drucker is a senior scientist at the Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital and professor of medicine at the University of Toronto. He has been working with GLP molecules for 35 years.
GLP-1 receptor agonists have been approved for treating type 2 diabetes for almost 20 years. Some of these agents are more recently approved at higher doses for treating obesity, which “prompts